BurningRock OncoScreen PlusTM Report
19/11/2019 BurningRock OncoScreen PlusTM is a NGS based assay that ... inhibitor (Navurizumab plus Ipilimumab) regardless of their PD-L1 expression.
get supplementary file.php?f=
Figures and Tables
Burning Rock DX OncoScreen Plus. ST25†/ST26/ST27/ST28. 1631. 523 hg19. 100. IDT. Integrated DNA Technologies xGen Pan-Cancer Panel ST04/ST05/ST06.
Cross oncopanelstudyreveals supp ?sequence= &isAllowed=y
RATIONALE-304: The association of tumor mutational burden with
The PFS benefit of tislelizumab plus chemotherapy vs showed that tislelizumab plus platinum-based chemotherapy significantly ... by OncoScreen Plus®.
Lu BGB A Biomarker AACR Poster
776P SHR-1701 a bifunctional fusion protein targeting PD-L1 and
a 520-gene panel (OncoScreen Plus Burning Rock Biotech) to identify genetic alter- ations that might be associated with treatment response in 39 pts.
775P Tremelimumab (T) + durvalumab (D) combined with
a 520-gene panel (OncoScreen Plus Burning Rock Biotech) to identify genetic alter- ations that might be associated with treatment response in 39 pts.
777P A prospective single-arm
https://www.annalsofoncology.org/article/S0923-7534(21)03448-7/pdf
HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired
520 cancer-related genes (OncoScreen Plus; Burning Rock. Biotech Guangzhou
372 Association of tumor mutation burden (TMB) and genomic
10/11/2021 for genomic testing (BurningRock OncoScreen Plus 520 NGS panel) were eligible. Patients were classified as having hyper-.
A .full
AACR 2022 RATIONALE-304: The association of tumor mutational
TMB scores were evaluated on baseline tumor and blood samples by OncoScreen Plus®. The Spearman's rank correlation of tTMB with bTMB was assessed. PFS by
Lu BGB A Biomarker AACR Abstract
Burning Rock Biotech Limited
core products including OncoScreen Plus™ and LungPlasma™
- oncoscreen plus burning rock
- onscreen plus panel